Mode
Text Size
Log in / Sign up
N/A N=99 Randomized Treatment

Efficacy and Mechanisms of CBT4CBT for Alcohol Use Disorders

Alcohol Use Disorder

Enrolled (actual)
99
Serious AEs
16.2%
Results posted
Mar 2023
Primary outcome: Primary: Percentage of Days Abstinent From Alcohol Use During Treatment as Measured by Timeline Follow Back — 49.26; 53.73; 47.57; 63.25 percentage of days abstinent — p=0.11

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Individual clinician-provided CBT (Behavioral); CBT4CBT (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Yale University
Primary completion
Dec 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Days Abstinent From Alcohol Use During Treatment as Measured by Timeline Follow Back
49.26; 53.73; 47.57; 63.25; 69.93; 71.07 0.11
PRIMARY
Percentage of Days Abstinent From Alcohol Use During 6-month Follow-up Period as Measured by Timeline Follow Back
69.26; 68.10; 73.28; 66.71; 75.86; 74.74 0.14

Summary

Evaluate the efficacy of CBT4CBT and clinician-delivered CBT relative to standard treatment for reducing alcohol use

Eligibility Criteria

Inclusion Criteria

Individuals will be included who:

  • Are 18 years of age or older.
  • Are applying for outpatient alcohol treatment and meet current DSM-5 criteria for alcohol use disorder, consuming at least 14/7 drinks (men/women) per week with at least 4 heavy drinking days reported in the past 28 days,
  • Are sufficiently stable for 8 weeks of outpatient treatment and can commit to a 6-month follow-up
  • Are willing to provide locator information for follow-up, and
  • Are fluent in English and have a 6th grade or higher reading level.

Exclusion Criteria

Individuals will be excluded who:

  • Have an untreated bipolar or schizophrenic disorder,
  • Have a current legal case pending such that incarceration during the 8-week protocol is likely,
  • Have been prescribed an alcohol pharmacotherapy (e.g., disulfiram, naltrexone) within the past two weeks, or
  • Are physically dependent on alcohol, opioids or benzodiazepines such that immediate medical detoxification is necessary for safety purposes (individuals demonstrating significant withdrawal symptoms would be eligible for re-screening following brief medical detoxification, which is arranged by RCS staff at triage).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02742246). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search